Sakalauskaite Sandra, Vaiciuniene Ruta, Kusleikaite-Pere Neda, Narbutiene Jurgita, Sauseriene Jolanta, Aukstakalniene Asta, Valius Leonas, Sitkauskiene Brigita
Laboratory of Immunology of the Department of Immunology and Allergology, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Department of Nephrology, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Pathogens. 2023 Feb 19;12(2):351. doi: 10.3390/pathogens12020351.
The prospective study was conducted to evaluate the prevalence of COVID-19 in kidney transplant patients in relation to their immune status after three doses of the BNT162b2 (Pfizer-BioNTech) vaccine during one post-pandemic year based on the experience of one center-Hospital of Lithuanian University of Health Sciences. Thirty-three patients were invited for a follow-up visit 3 to 6 weeks after anti-SARS-CoV-2 vaccination and were obliged to report having COVID-19 during the one-year post-pandemic period. Forty-two percent of patients developed antibody response against SARS-CoV-2 after the third dose of the vaccine. The number of COVID-19 cases during the post-pandemic period did not differ significantly between seropositive and seronegative patients. However, only seronegative patients were hospitalized due to COVID-19. The anti-SARS-CoV-2 antibody titer in seropositive patients correlated with a relative number of CD3 cells (R = 0.685, = 0.029). The CD8/CD38 ratio in this group increased 2-fold after the anti-SARS-CoV-2 vaccination. Higher antibody response to the COVID-19 vaccine was associated with better kidney function. The anti-SARS-CoV-2 antibody titer relation with the components of cellular immunity (CD3 cells and CD8/CD38 ratio) shows a role of both chains during the response to the anti-SARS-CoV-2 vaccine in kidney transplant patients.
基于立陶宛卫生科学大学医院这一中心的经验，开展了一项前瞻性研究，以评估在大流行后的一年中，肾移植患者接种三剂BNT162b2（辉瑞-生物科技公司）疫苗后，新冠病毒病（COVID-19）的流行情况与其免疫状态的关系。33名患者在接种抗SARS-CoV-2疫苗后3至6周被邀请进行随访，并被要求报告在大流行后一年内感染COVID-19的情况。42%的患者在接种第三剂疫苗后产生了针对SARS-CoV-2的抗体反应。在大流行后时期，血清阳性和血清阴性患者的COVID-19病例数没有显著差异。然而，只有血清阴性患者因COVID-19住院。血清阳性患者中抗SARS-CoV-2抗体滴度与CD3细胞相对数量相关（R = 0.685，P = 0.029）。该组中CD8/CD38比值在接种抗SARS-CoV-2疫苗后增加了2倍。对COVID-19疫苗的更高抗体反应与更好的肾功能相关。抗SARS-CoV-2抗体滴度与细胞免疫成分（CD3细胞和CD8/CD38比值）的关系表明，在肾移植患者对抗SARS-CoV-2疫苗的反应过程中，两者都发挥了作用。
